The (Pro)renin Receptor - A Regulatory Nodal Point in Disease Networks-Reference-Cited by-同舟云学术

The (Pro)renin Receptor - A Regulatory Nodal Point in Disease Networks

Published:2023-10 Issue:14 Volume:24 Page:1093-1098
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

Funke-Kaiser Heiko¹^ORCID,Unger Thomas²

Affiliation:

1. CCR Pharma (CCRP) Therapeutics, Berlin, Germany

2. CARIM - School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands

Abstract

Abstract: Experimental inhibition of the (pro)renin receptor [(P)RR] is a promising therapeutic strategy in different disease models ranging from cardiorenal to oncological entities. Here, we briefly review the direct protein-protein interaction partners of the (P)RR and the plethora of distinct diseases in which the (P)RR is involved. : The first structural work on the (P)RR using AlphaFold, which was recently published by Ebihara et al., is the center of this mini-review since it can mechanistically link the protein-protein interaction level with the pathophysiological level. : More detailed insights into the 3D structure of the (P)RR and its interaction domains might guide drug discovery on this novel target. Finally, antibody- and small molecule-based approaches to inhibit the (P)RR are shortly discussed.

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Reference73 articles.

1. Rahman A.; Matsuyama M.; Ebihara A.; Shibayama Y.; Hasan A.U.; Nakagami H.; Suzuki F.; Sun J.; Kobayashi T.; Hayashi H.; Nakano D.; Kobara H.; Masaki T.; Nishiyama A.; Antiproliferative effects of monoclonal antibodies against (Pro)renin receptor in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2020,19(9),1844-1855

2. Yamamoto H.; Kaneko K.; Ohba K.; Morimoto R.; Hirose T.; Satoh F.; Totsune K.; Takahashi K.; Increased expression of (pro)renin receptor in aldosterone-producing adenomas. Peptides 2013,49,68-73

3. Pareja F.; Brandes A.H.; Basili T.; Selenica P.; Geyer F.C.; Fan D.; Da Cruz Paula A.; Kumar R.; Brown D.N.; Gularte-Mérida R.; Alemar B.; Bi R.; Lim R.S.; de Bruijn I.; Fujisawa S.; Gardner R.; Feng E.; Li A.; da Silva E.M.; Lozada J.R.; Blecua P.; Cohen-Gould L.; Jungbluth A.A.; Rakha E.A.; Ellis I.O.; Edelweiss M.I.A.; Palazzo J.; Norton L.; Hollmann T.; Edelweiss M.; Rubin B.P.; Weigelt B.; Reis-Filho J.S.; Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun 2018,9(1),3533

4. Humphries H.; Brasch H.D.; van Schaijik B.; Tan S.T.; Itinteang T.; Expression of components of the renin-angiotensin system by the embryonic stem cell–like population within keloid lesions. Plast Reconstr Surg 2019,144(2),372-384

5. Shivapathasundram G.; Wickremesekera A.C.; Brasch H.D.; van Schaijik B.; Marsh R.W.; Tan S.T.; Itinteang T.; Expression of components of the renin-angiotensin system by the putative stem cell population within WHO Grade I meningioma. Front Surg 2019,6,23